A Besarab

Summary

Country: USA

Publications

  1. ncbi A study of parenteral iron regimens in hemodialysis patients
    A Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
    Am J Kidney Dis 34:21-8. 1999
  2. ncbi An indistinct balance: the safety and efficacy of parenteral iron therapy
    A Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA
    J Am Soc Nephrol 10:2029-43. 1999
  3. ncbi Iron and cardiac disease in the end-stage renal disease setting
    A Besarab
    Department of Medicine, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 34:S18-24. 1999
  4. ncbi Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
    A Besarab
    Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA
    J Am Soc Nephrol 11:530-8. 2000
  5. ncbi Preventing vascular access dysfunction: which policy to follow
    Anatole Besarab
    Division of Nephrology, Department of Medicine, University of West Virginia School of Medicine, Morgantown, WV, USA
    Blood Purif 20:26-35. 2002
  6. ncbi Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis
    A Gupta
    Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan, USA
    Kidney Int 55:1891-8. 1999
  7. ncbi The native arteriovenous fistula in 2007. Research needs
    A Besarab
    Department of Medicine, Henry Ford Health System, Detroit, Michigan, USA
    J Nephrol 20:668-73. 2007
  8. ncbi De novo once-monthly darbepoetin alpha treatment for the anemia of chronic kidney disease using a computerized algorithmic approach
    E Chalhoub
    Henry Ford Hospital, Division of Nephrology and Hypertension, Detroit, MI 48202, USA
    Clin Nephrol 76:1-8. 2011
  9. ncbi Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients
    A Besarab
    West Virginia University School of Medicine, Dialysis Unit, Ruby Memorial Hospital, Morgantown, WV, USA
    Nephrol Nurs J 28:429-34. 2001
  10. ncbi Defining a renal anemia management period
    A Besarab
    West Virginia University, Department of Medicine, Robert C Byrd Health Science Center, Morgantown, WV 26506, USA
    Am J Kidney Dis 36:S13-23. 2000

Collaborators

Detail Information

Publications43

  1. ncbi A study of parenteral iron regimens in hemodialysis patients
    A Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
    Am J Kidney Dis 34:21-8. 1999
    ..After weekly maintenance 25- to 100-mg iron dextran doses, iron indices can be measured after 1 week; a delay of 2 weeks is not necessary...
  2. ncbi An indistinct balance: the safety and efficacy of parenteral iron therapy
    A Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA
    J Am Soc Nephrol 10:2029-43. 1999
    ..Until these answers are known, the importance of carefully crafted iron therapy cannot be overstated...
  3. ncbi Iron and cardiac disease in the end-stage renal disease setting
    A Besarab
    Department of Medicine, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 34:S18-24. 1999
    ..Well-designed prospective studies are needed before the relationship between supplemental iron administration, excess iron, and cardiac disease can be firmly established...
  4. ncbi Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
    A Besarab
    Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA
    J Am Soc Nephrol 11:530-8. 2000
    ..Reticulocyte hemoglobin content increased only in the study group from 28.5 to 30.1 pg. It is concluded that maintenance of TSAT between 30 and 50% reduces rhEPO requirements significantly over a 6-mo period...
  5. ncbi Preventing vascular access dysfunction: which policy to follow
    Anatole Besarab
    Division of Nephrology, Department of Medicine, University of West Virginia School of Medicine, Morgantown, WV, USA
    Blood Purif 20:26-35. 2002
    ..Strategies and resources needed to achieve these policies are presented. The need for a team approach is emphasized...
  6. ncbi Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis
    A Gupta
    Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan, USA
    Kidney Int 55:1891-8. 1999
    ..Hemodialysis patients need iron to replenish ongoing losses. We evaluated the short-term safety and efficacy of infusing soluble ferric pyrophosphate by dialysate...
  7. ncbi The native arteriovenous fistula in 2007. Research needs
    A Besarab
    Department of Medicine, Henry Ford Health System, Detroit, Michigan, USA
    J Nephrol 20:668-73. 2007
    ..Given that the quality of the available literature in nephrology is often suboptimal, nephrologists need to pay special attention to methodology issues before embarking on expensive multicenter studies...
  8. ncbi De novo once-monthly darbepoetin alpha treatment for the anemia of chronic kidney disease using a computerized algorithmic approach
    E Chalhoub
    Henry Ford Hospital, Division of Nephrology and Hypertension, Detroit, MI 48202, USA
    Clin Nephrol 76:1-8. 2011
    ..We hypothesized that once-monthly (QM) algorithmically dosed darbepoetin ? (DA) and iron administration would successfully treat anemia of CKD in ESA-naïve CKD subjects...
  9. ncbi Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients
    A Besarab
    West Virginia University School of Medicine, Dialysis Unit, Ruby Memorial Hospital, Morgantown, WV, USA
    Nephrol Nurs J 28:429-34. 2001
    ..The implications of these findings for clinical practice are also discussed...
  10. ncbi Defining a renal anemia management period
    A Besarab
    West Virginia University, Department of Medicine, Robert C Byrd Health Science Center, Morgantown, WV 26506, USA
    Am J Kidney Dis 36:S13-23. 2000
    ..Treatment of anemia during the RAMP has the potential to ameliorate, or even prevent, significant future morbidity in patients with CRI...
  11. ncbi Effects of systemic hemodynamics on flow within vascular accesses used for hemodialysis
    A Besarab
    Department of Medicine, West Virginia University School of Medicine, Henry Ford Hospital, USA
    ASAIO J 47:501-6. 2001
    ..Cardiac output, MAP, and the arterial segment resistance influence QA in both access types and need to be considered when evaluating QA as part of the trend analysis for detecting access dysfunction...
  12. ncbi The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study
    R Provenzano
    Division of Nephrology, St John Hospital, 22201 Moross Road, Suite 150, Detroit, MI 48236, USA
    Clin Nephrol 67:306-17. 2007
    ..E.R.A.) to correct anemia at extended administration intervals in erythropoiesis-stimulating agent-na?ve patients with chronic kidney disease (CKD) not on dialysis and to determine its optimal starting dose...
  13. ncbi The native arteriovenous fistula in 2007. Surveillance and monitoring
    A Besarab
    Department of Medicine, Henry Ford Health System, Detroit, Michigan, USA
    J Nephrol 20:656-67. 2007
    ....
  14. ncbi Use of aspirin associates with longer primary patency of hemodialysis grafts
    Bradley S Dixon
    Division of Nephrology, University of Iowa College of Medicine, E 300D GH, 200 Hawkins Drive, Iowa City, IA 52242 1081, USA
    J Am Soc Nephrol 22:773-81. 2011
    ..In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA...
  15. ncbi Recommended standards for reports dealing with arteriovenous hemodialysis accesses
    Anton N Sidawy
    Committee on Reporting Standards for Arterio-Venous Accesses of The Society for Vascular Surgery and the American Association for Vascular Surgery, Washington, DC, USA
    J Vasc Surg 35:603-10. 2002
    ....
  16. ncbi Changes noted to KDOQI guidelines for vascular access
    Anatole Besarab
    Kidney Disease Outcomes Quality Initiative Workgroup for Vascular Access
    Nephrol News Issues 20:36. 2006
  17. ncbi Access monitoring is worthwhile and valuable
    Anatole Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48301, USA
    Blood Purif 24:77-89. 2006
    ....
  18. ncbi Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines
    Hugh C Rayner
    Birmingham Heartlands Hospital, United Kingdom
    Am J Kidney Dis 44:22-6. 2004
    ..CONCLUSION: The DOPPS will continue to monitor practice trends and explore whether greater application of guidelines will lead to fewer access complications and improved longevity for hemodialysis patients...
  19. ncbi Vascular access for hemodialysis: 2004 and beyond
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan, USA
    Curr Opin Nephrol Hypertens 13:623-9. 2004
    ....
  20. ncbi Vascular access: issues and management
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Mich, USA
    Contrib Nephrol 142:29-46. 2004
  21. ncbi Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. Pro
    Anatole Besarab
    Division of Nephrology and Hypertension, Department of Medicine, Henry Ford Hospital, Detroit, MI 48301, USA
    J Am Soc Nephrol 19:1629-31. 2008
    ..Here the various positions are examined from multiple perspectives...
  22. ncbi Dynamic venous access pressure ratio test for hemodialysis access monitoring
    Stanley Frinak
    Department of Medicine, Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 40:760-8. 2002
    ..We developed a method to prospectively monitor AVGs that uses an algorithm to calculate venous access pressure (VAP) during HD from the venous drip chamber pressure (VDP)...
  23. ncbi Utility of static pressure ratio recording during angioplasty of arteriovenous graft stenosis
    Arif Asif
    Division of Nephrology, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
    Semin Dial 19:551-6. 2006
    ..33 +/- 0.02). Qa increased significantly in 74 of 83 (89%) procedures (before = 572 +/- 201, after = 1109 +/- 368 ml/min; p < 0.001). SPR measurements can assist in hemodynamic assessment of an AVG during angioplasty procedure...
  24. ncbi More than a decade of experience and still no consensus: controversies in iron therapy
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Clin J Am Soc Nephrol 1:S1-3. 2006
  25. ncbi Interventional nephrology: from episodic to coordinated vascular access care
    Arif Asif
    Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    J Nephrol 20:399-405. 2007
    ..Challenges for the future include awareness of this subspecialty and development of training programs at academic centers on a larger scale...
  26. ncbi Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets
    Steven Fishbane
    Division of Nephrology, Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
    Clin J Am Soc Nephrol 2:1274-82. 2007
    ....
  27. ncbi Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial
    Marian Klinger
    Department of Nephrology and Transplantation Medicine, Medical University, Wroclaw, Poland
    Am J Kidney Dis 50:989-1000. 2007
    ..We examined its efficacy for Hb level correction when administered once every 2 weeks in erythropoiesis-stimulating agent-naive dialysis patients...
  28. ncbi The normal hematocrit study--follow-up
    Anatole Besarab
    N Engl J Med 358:433-4. 2008
  29. ncbi Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients
    Ryan D Kilpatrick
    Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
    Clin J Am Soc Nephrol 3:1077-83. 2008
    ..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated...
  30. ncbi Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Anatole Besarab
    Division of Nephrology and Hypertension, Department o f Medicine, Henry Ford Hospital, Detroit, Michigan, USA
    Clin Ther 29:626-39. 2007
    ..A continuous erythropoietin receptor activator (C.E.R.A.) is currently in development for the treatment of anemia in patients with chronic renal disease (CRD) receiving or not receiving dialysis treatment...
  31. ncbi Vascular mapping techniques: advantages and disadvantages
    Arif Asif
    Division of Nephrology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida 3136, USA
    J Nephrol 20:299-303. 2007
    ..This article presents advantages and disadvantages of the 3 mapping techniques and proposes a strategy to conduct vascular mapping in patients with chronic kidney disease...
  32. ncbi Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
    Am J Kidney Dis 40:439-46. 2002
    ..Recommendations of current US and European guidelines, which encourage the use of SC administration, not only have a sound rationale in terms of efficacy and safety, but also have a sound economic basis...
  33. ncbi What common practices in dialysis units can be altered to improve patient care?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan 48201, USA
    Semin Dial 17:16-7. 2004
  34. ncbi Effect of differing blood lines on delivered blood flow during hemodialysis
    Junaid Ahmed
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 44:498-508. 2004
    ..14; P = 0.04) with RS than CS tubing sets. CONCLUSION: Differences in [Q P - Q B ] occur both in vitro and in vivo, are much smaller with RS than CS tubing sets, and result in a greater delivered Kt/V of up to 0.14 for RS...
  35. ncbi Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia
    Nizar Attallah
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 47:644-54. 2006
    ..We conducted an open-label prospective study to assess the effect of vitamin C, an antioxidant, on EPO-hyporesponsive anemia in hemodialysis patients with unexplained hyperferritinemia...
  36. ncbi Antimicrobial locks: putting the lock on catheter infections
    Carol Manierski
    Department of Nephrology and Hypertension, Henry Ford Health System, Detroit, MI 48202, USA
    Adv Chronic Kidney Dis 13:245-58. 2006
    ..The objectives of this review are to evaluate the current body of evidence espousing the utilization of an antimicrobial lock solution in tunneled cuffed and uncuffed catheters that are utilized during chronic intermittent hemodialysis...
  37. ncbi How can the cardiac death rate be reduced in dialysis patients?
    Anatole Besarab
    Department of Medicine, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia 26506, USA
    Semin Dial 15:24-6. 2002
  38. ncbi Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202, USA
    Nat Clin Pract Nephrol 1:70-1. 2005
  39. ncbi Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia
    Uday S Nori
    Division of Nephrology, Henry Ford Hospital, Detroit, MI 48202, USA
    Am J Kidney Dis 48:596-605. 2006
    ..020. CONCLUSION: Antibiotic lock solutions are superior to the standard heparin lock alone in the prevention of CRBs, and low-dose gentamicin solution has efficacy similar to that of greater concentrations used in previous studies...
  40. ncbi Clinical epidemiology of arteriovenous fistula in 2007
    Pietro Ravani
    Clinical Epidemiology Unit, Memorial University of Newfoundland, St John s, Newfoundland, Canada
    J Nephrol 20:141-9. 2007
    ..Recent experience from the United States suggests that multidisciplinary management is the most appropriate approach to deal with all the multifaceted aspects of end-stage renal disease care and to increase the likelihood of success...
  41. ncbi Biology of arteriovenous fistula failure
    Prabir Roy-Chaudhury
    Division of Nephrology and Hypertension, University of Cincinnati, Cincinnati, Ohio 45267 0585, USA
    J Nephrol 20:150-63. 2007
    ..Finally, we will end with a brief description of some state-of-the-art clinical trials that are attempting to apply some of these novel therapeutic concepts to the recalcitrant clinical problem of AV fistula failure...
  42. ncbi Autogenous arteriovenous fistula options
    Lawrence M Spergel
    Dialysis Management Medical Group, San Francisco, California 94109, USA
    J Nephrol 20:288-98. 2007
    ..Optimizing autogenous options for hemodialysis requires vessel mapping and a surgeon's willingness to invest additional time and effort...
  43. ncbi Surgical salvage of the autogenous arteriovenous fistula (AVF)
    Lawrence M Spergel
    Dialysis Management Medical Group, San Francisco, CA 94109, USA
    J Nephrol 20:388-98. 2007
    ..These include strategies to salvage primary failed fistulae due to early thrombotic events or lack of maturation, ischemia, venous hypertensive problems, aneurysms and infections...